Olema Pharmaceuticals (OLMA) Proxy filing summary

Voting matters and shareholder proposals

• Four Class III director nominees are up for election to serve until the 2029 annual meeting and until successors are elected and qualified.

• Advisory approval of named executive officer compensation is on the agenda.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, will be voted on.

• Proxy holders may vote on any other business properly brought before the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends a vote FOR all four Class III director nominees.

• Nominees include Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport.

Executive compensation and say-on-pay

• Advisory vote on executive compensation for named executive officers is included as Proposal 2.